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In Brief
Mavilio et al. show that Timp3 impacts
gut-microbiome-related liver steatosis
and glucose intolerance. Loss of Timp3
potentiates gut microbiota dysbiosis,
leading to an increase in the development
of inflammatory and metabolic
abnormalities, which are mediated, in
part, through IL-6 signaling. Antibiotic-
mediated depletion of the microbiota
improved these metabolic and
inflammatory phenotypes.
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The effect of gut microbiota on obesity and insulin
resistance is now recognized, but the underlying
host-dependent mechanisms remain poorly unde-
fined. We find that tissue inhibitor of metalloprotei-
nase 3 knockout (Timp3/) mice fed a high-fat diet
exhibit gut microbiota dysbiosis, an increase in
branched chain and aromatic (BCAA) metabolites,
liver steatosis, and an increase in circulating soluble
IL-6 receptors (sIL6Rs). sIL6Rs can then activate in-
flammatory cells, such as CD11c+ cells, which drive
metabolic inflammation. Depleting the microbiota
through antibiotic treatment significantly improves
glucose tolerance, hepatic steatosis, and systemic
inflammation, and neutralizing sIL6R signaling re-
duces inflammation, but only mildly impacts glucose
tolerance. Collectively, our results suggest that gut
microbiota is the primary driver of the observed
metabolic dysfunction, which is mediated, in part,
through IL-6 signaling. Our findings also identify an
important role for Timp3 in mediating the effect of
the microbiota in metabolic diseases.
INTRODUCTION
The prevalence of obesity and its metabolic consequences,
including type 2 Diabetes mellitus, non-alcoholic steatohepati-
tis, and cardiovascular diseases, is increasing worldwide
(Anstee et al., 2013). Although genetics partially explain the
new cases, there are environmental causes, including diet,
physical activity, population density, and microbial exposure,
that contribute to disrupting lipid and glucose metabolism
(Tilg and Kaser, 2011). Several environmental inputs function
through low-grade activation of chronic inflammatory path-
ways, provoking metabolic inflammation and related insulin
resistance (Johnson and Olefsky, 2013; McNelis and Olefsky,This is an open access article under the CC BY-N2014). However, both the source of the inflammatory burden
and the extent to which inflammation primarily contributes to
metabolic disorders are still unresolved (Ferrante, 2013).
Recent studies have clearly identified the gut microbiota as an
environmental factor that influences its host’s metabolism to
develop chronic metabolic disorders (Khan et al., 2014; Mehal,
2013; Moschen et al., 2013).
In previous studies from our laboratory we identified tissue
inhibitor of metalloproteinase 3 (TIMP3), an extracellular ma-
trix-bound metalloprotease with anti-inflammatory and anti-
angiogenic properties, as an immunometabolic switch for
inflammatory signals involved in metabolic phenotypes, such
as glucose intolerance, reduced insulin action, and hepatic
steatosis (Cardellini et al., 2009, 2011; Federici et al., 2005;
Fiorentino et al., 2010; Menghini et al., 2009; Serino et al.,
2007). The effect of Timp3 on metabolic homeostasis is
thought to be a consequent of hyperactivation of inflammatory
signals at the tissue level, particularly tumor necrosis factor
alpha (TNF-a). In fact, TIMP3 modulates the activity of several
matrix metalloproteinases (MMPs), including MMP9, MMP14,
and the a disintegrin and metalloproteinase domain 17
(ADAM17), which, through the release of cytokine/chemokine
factors, control immune cells trafficking in inflamed tissue to
coordinate inflammation and tissue repair (Murphy et al.,
2008).
Overexpression of Timp3 frommonocyte CD68+ cells leads to
the improvement of the metabolic syndrome phenotypes along
with anti-inflammatory effects (Casagrande et al., 2012; Men-
ghini et al., 2012).
Whether inflammation anticipates metabolic abnormalities in
this model or vice versa is unresolved, and which factors antici-
pate the onset of the phenotype is still an unanswered question.
Coupling metabolome to metagenome profiling unveiled that
the inflammatory glucose-intolerant status determined by the
loss of Timp3 is related to dysbiosis at the gut level, and this is
first reflected in liver steatosis and then systemically perpetrated
via liver dependent release of sIL6R, which triggers metabolic
inflammation through the mobilization of inflammatory cells, pri-
marily CD11c+, toward the adipose tissue.Cell Reports 16, 731–743, July 19, 2016 ª 2016 The Author(s). 731
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Metabolic Phenotyping of Timp3/ Mice
(A) Fasting blood glucose levels were measured at different time points during an HFD (n = 5/each group; Student’s t test with Welch’s correction; **p < 0.01).
(B) Area under curve (AUC) during 120-min IPGTT of WT and Timp3/mice after 4 months on an HFD (n = 35/each group; data are mean ± SD, Student’s t test
with Welch’s correction ****p < 0.0001).
(C) Flow cytometry analysis of blood leukocytes was performed using monoclonal antibodies directed against monocyte markers CD11c, F4/80, and CX3CR1
(n = 5 in each group; data are mean ± SEM; Student’s t test with Welch’s correction; *p < 0.05, **p < 0.01).
(D) mRNA expression of CD11c, F4/80, and CX3CR1 in white adipose tissue (WAT), liver, andmuscle inWT and Timp3/ animals at 4months on an HFD. (n = 4 in
each group; data are mean ± SEM; Student’s t test with Welch’s correction; *p < 0.05).
See also Figure S1.RESULTS
Metabolic and Inflammatory Phenotype of Timp3/
Mice
Our initial screening showed that combining the loss of Timp3
with a high-fat diet (HFD) resulted in a progressive rise in fasting732 Cell Reports 16, 731–743, July 19, 2016blood glucose at 3 and 4 months (Figure 1A). After 4 months on
an HFD, Timp3/ mice had significantly higher glucose intoler-
ance compared with wild-type (WT) mice as shown from an area
under curve (AUC) calculation during an intraperitoneal glucose
tolerance test (IPGTT) (Figure 1B). Timp3/ mice fed an
HFD showed a decrease in body weight, an increase in total
Figure 2. Inflammatory Phenotyping of Timp3/ Mice
(A) Analysis of inflammatory infiltrate in the stromal vascular fraction (SVF) of WT and Timp3/ animals after 4 months on an HFD (n = 5 in each group; data are
mean ± SEM; *p < 0.05, ***p < 0.001, ****p < 0.0001 with one-way ANOVA with Sidak’s multiple comparison test).
(B) Expression of pro- and anti-inflammatory genes in SVF from Timp3/ mice and WT mice (n = 5 in each group; data are mean ± SEM; *p < 0.05 with Mann-
Whitney t test).
See also Figure S2.cholesterol, triglycerides, GOT-AST, and GPT-ALT, and an in-
crease in ALT/AST ratio, all mildly significant compared with
WT mice fed an HFD (Figures S1A and S1B). No difference
was observed in energy expenditure parameters (Figure S1C).
Circulating proinflammatory cells positive to CD11c already
increased at 2months in Timp3/mice fed an HFD; this was fol-
lowed by an increase in F4/80+ and CX3CR1+ cells (Figure 1C) at
3 months. Moreover, even several subpopulations of macro-
phage (F4/80+CX3CR1; F4/80+CX3CR1+) and dendritic cells
(CX3CR1+CD11c+ and CX3CR1 CD11c+) were significantly
increased (Figure S2A). Interestingly, analysis of the same
markers in peripheral tissue revealed increased mRNA expres-
sion of CD11c, F4/80, and CX3CR1 in white adipose tissue
(WAT), but not in liver andmuscle from Timp3/mice compared
with WT mice after 4 months on an HFD (Figure 1D). At the
same time point, we analyzed the presence of proinflammatory
leukocytes in the stromal vascular cells (SVCs) of WAT in WT
and Timp3/ animals. Cells expressing CD11c+, F4/80+, andCX3CR1+ were significantly increased (Figure 2A). mRNA
expression of interferon gamma (IFNg), the ligand for CX3CR1
(CX3CL1), interleukin 1 beta (IL1-b), the intercellular adhesion
molecule 1 (ICAM1), macrophage galoctose-type C-type lectin
1(MGL1), and C-C chemokine Receptor type 2 (CCR2) were
significantly overexpressed in Timp3/ mice fed an HFD
compared with the WT littermates fed an HFD without differ-
ences in anti-inflammatory cytokines, such as interleukin 10
(IL-10), interleukin 4 (IL-4), and interleukin 13 (IL-13) (Figure 2B).
The adipose fraction in Timp3/ mice fed an HFD showed no
reduction in most of the analyzed metabolic genes, such as
CCAAT/enhancer-binding protein beta (CEBP/b), CCAAT/
enhancer-binding protein alpha (CEBP/a), glucose transporter
type 4 (GLUT4), peroxisome proliferator-activated receptor
gamma (PPARg), hormone sensitive lipase (LIPE), adipose tri-
glyceride lipase or patatin-like phospholipase domain-contain-
ing 2 (PNPLA2), insulin receptor (INSR), fatty acid binding pro-
tein 4 (FABP4), and diacylglycerol o-acyltransferase 1 (DGAT1)Cell Reports 16, 731–743, July 19, 2016 733
Figure 3. Timp3/ Mice Fed an HFD Have Altered BCAA and AAA Pathways
(A) Top-ten metabolites significantly different in Timp3/mice compared with WT mice in fasting state. Two-way ANOVA analysis adjusted for diet, with an FDR
of 1%.
(B) PLS-DA (up) and random forest (down) approaches allowed to identify metabolites significantly different in Timp3/mice compared with WT mice on an ND
or on an HFD in the fasting state.
(C) Two principal metabolites belonging to the BCAA and AAA pathways: alpha-hydroxyisocaproate and indolelactate are shown as box plots, with median,
upper, and lower quartiles and maximum and mininum values in WT and Timp3/ mice fed both an ND and an HFD in fasting state (n = 6 per group; one-way
ANOVA with Sidak’s multiple comparison test; *p < 0.05, **p < 0.01, ***p < 0.001****p < 0.0001).
See also Figures S3 and S5 and Tables S1, S2, and S3.(Figure S2B). To understand which chemokine/cytokine may
sustain increased inflammatory burden in Timp3/ mice fed
an HFD, we performed a large-scale cytokine profile. Serum
cytokine array provided evidence for increased activity of the
innate immune system, as evidenced by increased granulo-
cyte-macrophage colony-stimulating factor (GM-CSF), mono-
kine induced by gamma interferon (MIG), interleukin 6 (IL-6),
and tumor necrosis factor alpha (TNF-a) in Timp3/ mice fed
an HFD compared with WT mice fed an HFD (Figure S2C).
These data show that the onset of inflammatory defects starts
with or shortly anticipates overt glucose intolerance in this model
and that this scenario is independent of obesity.
Metabolite Analysis Reveals Specific Defects in
Timp3/ Mice
To identify pathways linking inflammatory signals to metabolic
derangements, we performed a global metabolome screening734 Cell Reports 16, 731–743, July 19, 2016in serum from the fasting (ND and HFD) and fed state (HFD)
mice using targeted liquid chromatography-tandem mass spec-
trometry (LC/MS-MS) and gas chromatography-mass spec-
trometry (GC-MS) analysis.
Metabolomics analysis in the fasting state comprises a total
of 316 biochemicals (Table S1) with evidence of 100% predic-
tive accuracy at the random forest (RF) confusion matrix in
classifying groups into WT and Timp3/ in both ND and HFD
(Figure S3A). Two-way ANOVA analysis adjusted for diet and
with a false discovery rate (FDR) of 1% revealed several metab-
olites that discriminate between WT and Timp3/, including a
few belonging to branched chain and aromatic amino acids
(BCAA and AAA) metabolic pathways (Figures 3A, S3B, and
S3C; Table S2).
Univariate analysis with PLS-DA and random forest ap-
proaches led to the identification of similar metabolites able to
discriminate between WT and Timp3/ mice fed an HFD
Figure 4. Timp3/ Mice Fed an HFD Show Altered Expression for Metabolic and Inflammatory Signals in the Colon without Endotoxemia
(A) Real-time PCR analysis of RNA extracted from liver, muscle, white adipose tissue (WAT), and colon tissues of the Timp3/ mice compared with the WT
littermates fed an HFD. (n = 5 in liver, muscle, and WAT; n = 9 in colon; data are mean ± SEM; **p < 0.01, ****p < 0.0001 by Mann-Whitney t test; a.u.)
(B) H&E-stained colonic sections of WT and Timp3/ mice at 4 months on an HFD. Upper, 43; lower, 203.
(C and D) Real-time PCR analysis on RNA extracted from colon tissue of the Timp3/ mice compared with the WT littermates fed an HFD. (C) Inflammatory
genes, (D) wall permeability genes. (n = 9 data are mean ± SEM; *p < 0.05, **p < 0.01 by Mann-Whitney t test).
(E) Quantification of 16S DNA concentrations in MAT (mesenteric adipose tissue), EAT (epididimal adipose tissue), and peripheral blood mononuclear cells
(PBMCs) of Timp3/ mice compared with WT animals. (n = 5 per group; data are mean ± SEM.) Serum levels of lipopolysaccharide (LPS) in WT and Timp3/
mice fed an HFD (n = 10 per group).
See also Figure S4.(fasted), with alpha-hydroxyisocaproate and indolelactate al-
ways as top predictors. The same analysis in WT and Timp3/
mice under a ND showed that BCAA and AAA metabolic path-
ways slightly differed in the two strains, but only alpha-hydroxyi-
socaproate was among the top predictors in PLS-DA and
random forest analysis (Figures 3B, 3C, and S3D).
This finding, again, suggests that a genotype/HFD interaction
impinges on BCAA and AAA metabolic pathways.
To understand if the defective metabolism of BCAA could
be explained by defects in the enzymes controlling the rate-
limiting steps, we analyzed mRNA expression of the branched
chain alpha-ketoacid dehydrogenase (BCKDH) complex and
branched-chain-amino-acid transaminase (BCATm, encoded
by BCAT2 gene) in the most metabolically active tissue, such
as liver, muscle, WAT, and colon.
The colon is a highly metabolically active organ with functions
not only for the remainder of the digestive tract, but also for the
peripheral organs above mentioned.In Timp3/mice fed an ND compared to WT mice fed an ND,
we observed a significant decrease of BCKDH beta subunit in
WAT and a modest decrease in muscle BCAT1 (Figure S4).
mRNA expression analysis of BCKDH isoforms in themetabol-
ically active tissues revealed, on HFD challenge, a significant
decrease, especially in the colon of Timp3/ mice fed an HFD
compared with WT mice fed an HFD, whereas no differences
were found in BCAT1/2 mRNA expression (Figure 4A).
Given the fact that several metabolites varying between WT
and Timp3/ mice are derived from the gut microbiome, such
as indole derivatives, we investigated whether loss of Timp3
has an impact on gut inflammation, permeability, and gut micro-
biota composition.
At the colon level, Timp3/ mice fed an HFD revealed
increased evidence for inflammatory activation, including
massive lymphoid infiltrate, as evidenced by H&E staining (Fig-
ure 4B). At the molecular level, we observed altered innate im-
mune genes. In particular, we detected an increased expressionCell Reports 16, 731–743, July 19, 2016 735
of interleukin 1 beta (IL-1b), interleukin 6 (IL-6), TNF-a, and
monocyte chemotactic protein 1 (MCP-1), whereas we found a
significantly decreased expression of interleukin 13 (IL-13) and
defensins, such as as Defa-1, Defb-3, as well as altered acquired
immunity genes, such as decreased expression of the aryl hy-
drocarbon receptor (AHR), RAR-related orphan receptor gamma
(Rorg), and Forkhead box protein O1 (FoxO1) in Timp3/ mice
fed an HFD compared with WT mice fed an HFD (Figure 4C).
No changes were observed in genes related to gut permeability,
such as JAM-A, ZO-1, and Occludin (Figure 4D). Further, we did
not observe differences in the analysis of bacterial translocation
in mesenteric adipose tissue (MAT), epididimal adipose tissue
(EAT), and peripheral blood mononuclear cells (PBMCs) or in
the serum levels of lipopolysaccharide (LPS) (Figure 4E).
Overall, these data suggest the Timp3/HFD interaction in-
duces gut microbiome dysbiosis, resulting in the generation of
signals at the gut level that could influence systemic metabolic
functions, including glucose tolerance. To corroborate this hy-
pothesis, we performed a second experiment with Timp3/
and WT mice fed a ND or an HFD. However, to have sufficient
material for 16S metagenomics, mice were sacrificed in the fed
state. Since we previously found the main differences in HFD,
we also performed another metabolomics screening to be able
to compare metabolites and 16S metagenomics in the same
mice at the same time point (Table S3). PLS-DA, random forest,
and functional class scoring analysis again revealed metabolites
andmetabolic pathways linked to BCAA (isoleucine, leucine, and
valinemetabolic pathways), as well as AAA (tryptophan pathway)
(Figures S5A–S5C).
Because of our findings that several metabolites, particularly
AAA derivatives, are gut microbiome dependent, we performed
analysis comparing 16S bacterial DNA at the caecal level in
Timp3/ and WT mice, in both ND and HFD conditions (Tables
S4, S5, S6, S7, and S8). At the phylum level we observed differ-
ences, particularly in theND state (Figure S6). Because themeta-
bolic phenotypeswere evident on interaction of the loss of Timp3
and HFD, we focused particularly on this context. Analysis of
families and genera revealed several differences with consistent
modulation inMycoplasmataceae/Mycoplasma, Prevotellaceae/
Prevotella, Sphingomonadaceae/Sphingomonas, Pasteurella-
ceae/Pasteurella, Helicobacteraceae/Helicobacter, Oxalobac-
teraceae/Massilia, and Lactobacillaceae/Lactobacillus (Tables
S4, S5, and S6). The first two were also evident when comparing
WT and Timp3/ mice fed an ND (Tables S7 and S8).
To investigate whether gut microbiota contributes to the in-
flammatory and diabetic phenotype observed in Timp3/
mice and to test the relevance of our findings in a clinical
perspective, we performed two different treatments in both WT
mice fed an HFD and Timp3/ mice fed an HFD.
In the first approach, we modulated the microbiota in WT
mice fed an HFD and Timp3/ littermates fed an HFD using a
combination of broad-range antibiotics for 4 weeks (Abx) (ampi-
cillin/metronidazole/norfloxacin 1g/l in drinking water). Results
showed improved fasting and fed blood glucose levels and
glucose tolerance in antibiotic-treated Timp3/ mice fed an
HFD, compared with untreated Timp3/ mice fed an HFD (Fig-
ures 5A and 5B). Since Timp3/ mice fed an HFD show liver
steatosis (Fiorentino et al., 2010) and signs of non-viral hepatitis,736 Cell Reports 16, 731–743, July 19, 2016we analyzed liver histology. Surprisingly, we observed that Abx
treatment improved microvescicular, macrovescicular, and
lobular inflammation, as well as improved ADAM17 convertase
and MMPs activities (Figures 5E and S7A), in Timp3/ mice
fed an HFD compared with WT mice fed an HFD (Figures 5C
and 5D). Remarkably, the BCKDH subunits of mRNA expression
in liver and colon after Abx treatment were significantly improved
in Timp3/ mice fed an HFD (Figures 5F and 5G).
Next, we looked for agents that could translate the effect of
dysbiosis at the systemic level. IL-6 was the most significantly
increased cytokine in Timp3/ mice fed an HFD (Figure S2C),
and loss of Timp3may potentially increase, via ADAM17, the sol-
uble form of the IL-6 receptor (sIL6R) from liver and other tissues
(Scheller et al., 2014; Schumacher et al., 2015; Yan et al., 2016).
Our results confirmed that Timp3/ mice fed an HFD showed
significantly increased levels of IL-6, sIL6R, and IL-6/sIL6R inter-
action in serum (Figure 6A), as well as significantly increased
levels of IL-6 in liver and WAT (Figure 6B).
Therefore, in the second approach we tested the hypothesis
that dysbiosis in Timp3/mice was responsible for the increase
of the IL-6/sIL6R complex and, in turn, for myeloid cells traf-
ficking. When IL-6 binds to its soluble receptor, a trans-signaling
alternative pathway is engaged, recruiting proinflammatory cells
and amplifying the inflammatory cascade in several diseases
(Scheller et al., 2014).
First, we investigated the levels of both IL-6 and soluble IL6-
Ralpha in a serum sample of Timp3/ and WT mice fed an
HFD and subjected to antibiotic treatment compared with un-
treated samples.
We found decreased expression of both the soluble IL6R and
IL-6 in treated compared with untreated samples serum from
Timp3/ mice fed an HFD, while no change was observed in
the WT serum samples (untreated versus treated) (Figures 6C
and 6D). Similar results were observed in analysis of CD11c+
circulating cells in blood and SVC derived from WAT (Figure 6E),
in Timp3/mice fed an HFD and treated with Abx compared to
untreated Timp3/ mice fed an HFD and no differences be-
tween the two WT groups.
These data suggest that the gut microbiome possibly influ-
ences the sIL6R-CD11c+ axis via hepatic steatosis. However,
whether these effects entirely depend on the gut microbiome
and the associated dysbiosis or low-grade inflammation of the
liver could not be revealed by this experiment. To elucidate
this issue, we performed an intervention experiment to block
the gut microbiome/liver-sIL6R-CD11c+ axis specifically in the
second part (from liver to periphery) using soluble gp130Fc, a
decoy protein that blocks IL-6/sIL6R trans-signaling. Treatment
with soluble gp130Fc (sgp130Fc) improved fasting glycaemia
after 1 month, glucose tolerance, and fasting insulin at
2months after injection in Timp3/mice compared to untreated
Timp3/ mice (Figures 7A and 7B, respectively).
In Timp3/ mice treated with sgp130Fc we found a
decreased number of circulating CD11c+ cells and several proin-
flammatory subpopulations in the blood at 1 month and in SVC
at 2 months from injection, while no differences were observed
in the blood at 2 months from injection in either Timp3/
or WT mice (Figures 7C–7F). Consistent with our hypothesis,
treatment with sgp130Fc did not improve features of liver
Figure 5. Antibiotic Treatment Improves Features of Metabolic Syndrome, Low-Grade Inflammation, and ADAM17 Activity in Timp3/Mice
Fed an HFD
(A) Fasting and fed blood glucose levels (left) (n = 6 per group; data are mean ± SEM; Student’s t test with Welch’s correction **p < 0.01) and fasting insulin level
(right) in antibiotic-treated WT and Timp3/ mice fed an HFD compared to untreated controls (n = 6 per group; data are mean ± SEM; one-way ANOVA with
Tukey’s multiple comparison test; *p < 0.05 per fasting insulin.
(B) IPGTT test of WT (left) and Timp3/ mice (right) after in vivo antibiotic treatment compared to an untreated control.
(C and D) Histology of liver inWT (left) and Timp3/mice fed an HFD (right) (H&E stain; scale bar, mm) after antibiotic treatment compared with untreated controls
(C) and the percentage of microvescicular, macrovescicular, and lobular inflammation (D) (n = 4–5 per group; data are mean ±SEM; one-way ANOVAwith Sidak’s
multiple comparison test; *p < 0.05, **p < 0.01, ***p < 0.001).
(E) ADAM17 activity in untreatedWT and Timp3/mice fed an HFD compared with antibiotic-treated littermates (n = 5 per group; data aremean ±SEM; one-way
ANOVA with Sidak’s multiple comparisons test; *p < 0.05, ***p < 0.001).
(F andG)mRNA expression of BCKDHa and BCKDHb subunits in liver (F) and colon (G) before and after antibiotic treatment (Abx) inWT and Timp3/mice fed an
HFD (n = 9 for colon analysis; n = 5 for liver analysis; data are mean ± SEM; *p < 0.05 **p < 0.01, ****p < 0.0001 by Mann-Whitney t test).
See also Figure S6 and Tables S4, S5, S6, S7, and S8.steatosis, inflammation, ADAM17 convertase, and MMPs activ-
ities in Timp3/ mice (Figures 7G–7I and S7B).
DISCUSSION
We have identified a pathway coordinated by Timp3 active at the
gut level. Gut dysbiosis in Timp3-null mice leads to liver steatosis
and the release of soluble IL6R. In turn, increased sIL6R results in
the accumulation of CD11c+ cells in peripheral tissues and in in-
sulin resistance.Data from other models clearly showed that activation of in-
flammatory pathways at the gut level has a broad role in glucose
homeostasis at the systemic level (Cox et al., 2015; Denou et al.,
2015; Duca et al., 2014; Everard et al., 2013; Tremaroli and
Ba¨ckhed, 2012). The mechanistic role of the intestinal immune
system as a primary sensor in the cross-talk between nutrients,
gut microbes, and hosts in metabolic disorders has been
recently identified (Everard et al., 2014).
In previous analysis we showed that the interaction of Timp3
deficiency with genetic insulin resistance during a short dietaryCell Reports 16, 731–743, July 19, 2016 737
Figure 6. IL-6 and sIL6R Levels in Blood, Liver, and WAT
(A) Serum levels of IL-6 and sIL6Ra analyzed by western blot (left) and graphic representation of optical density (OD) of IL-6 and sIL6R protein levels in serum,
which were normalized to loading (right) (n = 4 per group; data are mean ± SEM; one-way ANOVA with Sidak’s multiple comparison test; *p < 0.05, **p < 0.01,
***p < 0.001).
(B) IL-6 expression analyzed by western blot in liver and WAT of WT and Timp3/mice fed an HFD (left) and graphic representation of optical density (OD) (n = 4
data are mean ± SEM; *p < 0.05 by Mann-Whitney t test.
(C) Serum levels of IL-6 and sIL6Ra protein levels in untreated WT and Timp3/ mice fed an HFD compared with antibiotic-treated littermates analyzed by
western blot (left) and graphic representation of optical density (OD), which were normalized to loading (right) (n = 3 per group; data are mean ± SEM; one-way
ANOVA with Sidak’s multiple comparison test *p < 0.05; **p < 0.01).
(D) ELISA of sIL6R in sera of untreated WT and Timp3/mice fed an HFD compared with antibiotic-treated littermates. (n = 4 per group; data are mean ± SEM;
one-way ANOVA with Sidak’s multiple comparison test; *p < 0.05, ***p < 0.001).
(E) Flow cytometry analysis of blood leukocyte and stromal vascular cells (SVCs) was performed using monoclonal antibodies directed against dendritic cells
(CD11c+). In antibiotic-treated Timp3/ mice fed an HFD we found a decrease in the percentage of CD11c+ population compared with littermate controls,
whereas no difference was found in treated WT mice fed an HFD compared with the control after 4 weeks of antibiotic treatment (Abx) (n = 5 per group; data are
mean ± SEM. *p < 0.05 by Mann-Whitney t test, a.u.).challenge, as well as loss of Timp3 in a prolonged dietary chal-
lenge resulted in associated increased expression of both in-
flammatory and de novo lipogenic genes, such as IL-6 and
SCD-1 (Fiorentino et al., 2010; Menghini et al., 2009). However,
these studies neither clarified how the nutritional stimulus was
reflected into metabolic inflammation in vivo nor determined
whether a tissue is affected first and consequently spreads sig-
nals to others.
It has been recently shown that sIL6R is involved in CD11c+
accumulation inWAT despite an apparently minor effect on insu-
lin resistance. However, which signals are upstream of the hy-738 Cell Reports 16, 731–743, July 19, 2016peractivation of the sIL6R trans-signaling pathway from the liver
to periphery remained untested (Kraakman et al., 2015). Our data
help to fill these gaps.
We show that sIL6R is higher in concomitance of the loss
of Timp3. Our work suggests that gut dysbiosis, indepen-
dent of gut bacterial translocation, affects both liver steato-
sis and the release of sIL6R to activate IL-6 trans-signaling
and CD11c+ recruitment pathway. Whether this axis is
acting specifically at the liver level or whether other tissues
contribute remains to be established in future works with
targeted models.
Figure 7. Inhibition of sIL6R Signaling Controls CD11c+ Trafficking with Mild Effects on Glucose Tolerance and No Effect on Steatosis and
ADAM17 Activity
(A) Soluble gp130Fc (sgp130Fc) effect on metabolic status: fasting blood glucose 1 month post-injection in WT and Timp3/ mice fed an HFD injected with
sgp130Fc (chimera) compared with littermates injected with PBS (vehicle) (n = 4 data are mean ± SEM; one-way ANOVA with Sidak’s multiple comparison test;
*p < 0.05, **p < 0.01.
(B) Intraperitoneal glucose tolerance test and area under curve (AUC) (left) and fasting insulin level (right) after twomonths from in vivo treatment of Timp3/mice
with sgp130Fc (chimera) compared with Timp3/ mice fed an HFD and injected with PBS (vehicle). (n = 9; data are mean ± SEM; *p < 0.05 by Mann-Whitney
t test; a.u. per AUC; one-way ANOVA with Sidak’s multiple comparison test per fasting insulin; *p < 0.05, **p < 0.01).
(C–F) Effect on CD11c+ cells in blood at 1 month (C) and 2months (D) and in SVC at 2months (E) after injection of soluble gp130Fc in Timp3/mice and in SVC at
2 months (F) after injection of soluble gp130Fc in WT mice (n = 4/each group; Bonferroni’s test *p < 0.05).
(G and H) Histology of liver in WT and Timp3/ mice fed an HFD (H&E stain: scale bar, mm) after treatment compared with littermate controls (G) and the
percentage of microvescicular, macrovescicular, and lobular inflammation (H).
(I) ADAM17 activity in WT and Timp3/mice fed an HFD and injected with sgp130Fc (chimera) compared with littermates injected with PBS (vehicle) (n = 4 data
are mean ± SEM; one-way ANOVA with Sidak’s multiple comparison test; ***p < 0.001).
See also Figure S7.The role of CD11c+ accumulation as part of the ATM burden in
obesity and the consequent effect on glucose intolerance has
been recently discussed (Patsouris et al., 2008; Wentworth
et al., 2010; Wu et al., 2010). Our results are in accordance
with those of Kraakman et al. (2015) by showing that the insu-
lin-sensitizing effect of sgp130Fc is mild and less efficacious
compared with antibiotic treatment, despite a strong preventiveeffect on SVC-CD11c+ accumulation in both cases. However,
we cannot exclude that the CD11c+ cells have insulin resistance
effects in tissues other than WAT or that sub-types of CD11c+
cells exhibit different phenotypes (Li et al., 2010; Wentworth
et al., 2010). Our data support that CD11c+ accumulation in
ATM is part of a broader scenario in which changes in gut-related
metabolites may influence glucosemetabolism and that immuneCell Reports 16, 731–743, July 19, 2016 739
cells accumulate at the peripheral level as part of a systemic
response.
Our data also point to the regulation of the interaction between
the gut immune system and nutrients as a more efficacious
target for the control of glucose homeostasis rather than the ad-
ipose immune system. Which agents trigger local inflammation
remains unknown, although it is tempting to speculate about
the possible influence of gut microbiome-related metabolites.
Several groups have investigated the link between gut micro-
biome, the associated metabolites, and the influence on host
metabolism. Short chain fatty acids (SCFA) have been long
considered a major driver to preserve insulin sensitivity as a
response to changes in bacterial genus, such as Roseburia
and Faecalibacterium prausnitzii. SCFA released from the gut
may interact with GPR41 to affect adipose tissue metabolism
(Karlsson et al., 2013).
Our metabolomics screening unveils a potential role for
aromatic amino acid derivatives, generally considered important
as uremic toxins, also in early phases of insulin resistance
(Koppe et al., 2013; Lustgarten et al., 2014). However, the
increase in indole compounds, particulary indoxylsulfate, is
consistent with accumulation of uremic toxins as an effect of
diabetic nephropathy observed in Timp3/ (Fiorentino et al.,
2013a; Fiorentino et al., 2013b).
Branched chain amino acids (BCAAs) have been also associ-
ated with insulin resistance and cardiovascular disorders in hu-
man subjects (Laferre`re et al., 2011; Lynch and Adams, 2014;
Newgard et al., 2009). The basis for defective BCAA metabolism
in metabolic disorders, such as obesity, diabetes, and athero-
sclerosis, is still a matter of debate. Our data show that BCKDH,
the rate-limiting enzyme in BCAA metabolism, is downregulated
in a model combining nutrient excess to Timp3 deficiency. How-
ever, antibiotic treatment reverses this defect, suggesting a link
between gut dysbiosis and BCAAmetabolism, particularly in the
colon itself and in the liver.
The gut microbiota is now accepted as a major component in
metabolic disorders independent of genetics, as well as a plau-
sible cause to explain how social changes in only one century
has so dramatically increased the prevalence of obesity and
related complications (Ridaura et al., 2013). Knowledge of gut
microbiome is still poor, although recent studies have identified
some bacterial genus and species causally linked to the onset
of obesity and diabetes.
We have previously shown that Timp3/ mice suffer from
increased susceptibility to inflammatory bowel disease, where
the gut microbiome may also play a part (Monteleone et al.,
2012). The role of innate immune mechanisms in regulating
metabolic disorders through modulation of gut microbiota was
reported in models with deletion of crucial pattern recognition
receptors (TLR2, TLR4, and TLR5) or adaptors, such as
(Myd88) (Kellermayer et al., 2011; Kim et al., 2012; Vijay-Kumar
et al., 2010). Ablation of TLR2 in mice fed an HFD under germ-
free conditions increases the risk of metabolic syndrome,
particularly through regulation of Firmicutes and increased
LPS absorption. In our results we found that TIMP3 modulates
the gut microbiota at family levels, suggesting a different way
to affect host-microbial interactions. Because antibiotics, but
not sgp130fc chimera treatment, dampened ADAM17 activity740 Cell Reports 16, 731–743, July 19, 2016in the liver (although we cannot exclude that other tissues are
also affected in a similar manner), it is intriguing to speculate
about a role for gut microbiome-related metabolites on
ADAM17. However, our results do not allow us to discriminate
whether the increased activity of ADAM17 is a direct effect of
gut microbiome metabolism or whether other messengers
mediate this effect.
A limitation of the present results is that our data do not clarify
whether TIMP3 has a direct role on the metabolic abnormalities
or whether TIMP3-related gut dysbiosis mediate metabolic ab-
normalities independent from TIMP3. To discern between these
possibilities, future studies must be performed to address
whether dysbiotic microbiota transplantation from Timp3/ to
WTmice is sufficient to induce phenotype inWTmice, eventually
using co-housing approach.
Our data suggest that beside the paradigm of bacterial trans-
location as an essential step for development of obesity and its
consequences, an alternative model characterized by metaboli-
cally active dysbiosis exists and should be exploited in human
subjects with diabetes.
In conclusion, we observed that TIMP3 affects gut micro-
biome-related liver steatosis and glucose intolerance in mice
challenged with nutrient excess, suggesting that modulation of
the gut microbiome via TIMP3 is a new possible mechanism to
improve glucose intolerance status.
EXPERIMENTAL PROCEDURES
Mouse Model and Metabolic Tests
Timp3/ mice on a C57/BL6 background, as well as the metabolic testing
procedures, have been previously described (Federici et al., 2005; Menghini
et al., 2009; Mohammed et al., 2004; Serino et al., 2007). All animal procedures
are in accordance with the Guide for the Care and Use of Laboratory Animals
published by the NIH (publication no. 85–23, revised 1996), approved by the
University Hospital of Tor Vergata Animal Care Facility, and have been previ-
ously described (Fiorentino et al., 2013a).
WT and Timp3/ mice lines were housed in separated cages, with each
cage containing 3–4 mice of the same genotype and fed an HFD (HFD) (60%
of calories from fat; Research Diets) or normal diet (ND) (10% calories from
fat, Good Laboratory Practices [GLP]; Mucedola S.r.l.) for 16 weeks after
weaning. The sgp130Fc was administered in the same conditions as above,
starting at week 8 of the HFD and ending at week 16 of the HFD.
After 12 weeks on an HFD, mice (in the same conditions as above) were
separated in isolated autoclaved cages (one mouse per cage), and antibiotics
were administered in the water for a duration of 4 weeks, while the HFD
regimen wasmaintained. All the disposals used during the antibiotic treatment
were sterile.
Serum Measurements
ELISA was performed for the soluble IL-6 receptor (MyBioSource); plasma in-
sulin was assessed using an ultrasensitive mouse insulin ELISA kit (Mrcodia) in
accordancewith themanufacturer’s instructions. The remaining samples were
stored in appropriate (endotoxin-free) vials at 80C until the endotoxin anal-
ysis, which was performed using a commercially available kit (limulus amebo-
cyte lysate [LAL], Chromogenic Endpoint Assay, Hycult Biotechnology). To
neutralize endotoxin inhibitors, serum was heated at 70C for 30 min before
being processed.
ADAM17 Activity
ADAM17 activity was determined using the SensoLyte 520 TACE Activity
Assay Kit (AnaSpec), in accordance with the manufacturer’s protocol. 30 mg
of tissue proteins were used for the assay. Reaction was started by adding
40 mM of the fluorophoric QXL520/5FAM FRET substrate. Fluorescence of
the cleavage product was measured in a fluorescence microplate reader
(Beckman Coulter DTX 800) at lex 490 nm and lem 520 nm.
Assay Citokine
The cytokines and chemokines profiles of the sera mouse were analyzed using
RayBio Mouse Cytokine Antibody Array (Cat# AAM-CYT-3, RayBiotech), in
accordance with the manufacturer’s instruction.
Isolation of Adipocytes and SVF
White adipose tissue (WAT) separationwas performed as previously described
(Fabrizi et al., 2014).
Flow Cytometry Analysis
Cells from the stromal vascular fraction (SVF) of adipose tissue and blood cells
were stained with CD11c (Milteny Biotec), CD11b (Miltenyi Biotec), F4/80 (Mil-
tenyi Biotec), and CX3CR1 (R&D System). For the blood, in brief, 200 ml were
collected retro-orbitally and anticoagulated with heparin. Red blood cells were
lysed with RBC Lysis Buffer (EBioscience) and then stained with fluorescently
labeled primary antibodies.
Samples were analyzed using a FACScalibur (BD Bioscience) running BD
Cellquest Pro and analyzed with Flow JO (TreeStar). Monocytes were defined
as CX3CR1+ and CD11b+, whereas subpopulations of macrophages were
defined as F4/80+CX3CR1, and dendritic cells were defined as CD11c total
and CD11c+CX3CR1+ and CX3CR1.
Gene Expression Analysis by qRT-PCR
Total RNA was isolated from tissue using TRIzol Reagent (Invitrogen). 2 mg of
total RNA were reverse transcribed into cDNA using the High Capacity cDNA
Archive Kit (Applied Biosystems). A quantitative real-time PCR was performed
using an ABI PRISM7700 System and TaqMan reagents (Applied Biosystems).
Each reaction was performed in triplicate using standard reaction conditions,
and the cycle threshold (Ct) value was normalized in mouse by b-actin.
Western Blot
Preparation of tissue lysates, quantification, and immunoblot analysis were
performed as previously described (Marino et al., 2014). Antibodies to IL-6
(Invitrogen), sIL6R (R&D Systems), and actin (Santa Cruz Biotechnology)
were used.
Metabolomics Analysis
Targeted global metabolomic analysis was carried out by Metabolon. See
the Supplemental Experimental Procedures for a complete description of
methods.
Histological Analysis
Liver and intestinal tissues were obtained from mice fed an HFD; specimens
were fixed in10% paraformaldehyde and embedded in paraffin. 10-mm
consecutive sections were then mounted on slides and stained with H&E
(Sigma-Aldrich).
The severity of nonalcoholic fatty liver diseasewas based on the amount and
types of fat (macrovescicular and microvescicular), extent of inflammation,
presence of cell degeneration (acidophil bodies, ballooning, and Mallory’s hy-
aline), or necrosis and degree of fibrosis as described.
16S rRNA and Metagenomics Analysis
The caecal content was collected postmortem from each mouse (five/group)
and was stored at 80C.
The DNA was extracted from the caecal content of mice using the QIAamp
DNAStoolMiniKit (QIAGEN), inaccordancewith themanufacturer’s instructions.
Microbial community composition was assessed by sequencing hypervari-
able regions (HVR) 5–6 of the 16S rRNA (GENOMNIA, EBI metagenomics:
PRJEB8244) derived from caecal samples of both chow diet (ND) and high-
fat diet (HFD) animals.
Antibiotics Treatment
After 4 months on an HFD, WT and Timp3/ mice were subjected to antibi-
otics treatment. Norfloxacin, metronidazole, and ampicillin (1 g/l each) (SigmaAldrich) were added to the drinking water for 4 weeks as previously described
(Denou et al., 2015).
Injection of the Soluble Form of gp130Fc-Protein
WT and Timp3/ mice (n = 20/each) fed an HFD for 2 months were injected
intraperitoneally twice with a solution (20 mg/animal) of the soluble form of
gp130Fc (R&D Systems).
Glycaemia were routinely checked in fasted and fed animals. After injection,
the number of circulating myeloid cells (as CD11c, CD11b, CX3CR1, and F4/
80) was determined by flow cytometry.
Statistical Analysis
Results of the experimental studies are expressed asmeans ± SEM. Statistical
analyseswere performedwith GraphPad Prism (v.6.02) and R (v.3.0.2). Groups
were compared using a two-tailed unpaired Student’s t test and Mann-Whit-
ney test; one- or two-way ANOVA with post hoc comparisons is as indicated.
Multiplicity was taken into account by means of Benjamini and Hochberg
correction, and hence the threshold for significance is data dependent. In
this context, Benjamini and Hochberg (1995) correction guarantees a false dis-
covery rate below 0.05 (Farcomeni, 2006, 2007, 2008). Linear correlation anal-
ysis was performed using the Spearman test. Values of p < 0.05 have been
considered statistically significant. Pathway analysis was performed bymeans
of functional class scoring (FCS): gene-level statistics (p values from one or
two-way ANOVA) have been aggregated by means of the median, and then
the statistical significance of the pathway has been assessed bymeans of per-
mutation. The top-ten pathways are considered as worth mentioning and
further investigating (Qureshi and Sacan, 2013; Khatri et al., 2012).
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